

Supplementary Material

Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints From a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study

Michel Lanteri-Minet^{1,2}, Timothy Smith³, Catherine Nalpas⁴, Luz M Ramirez⁵, Alexandra Thiry⁶, Shannin McCollum⁶, Sara Ramaker⁷, Robert Fountaine⁶

¹Pain Department and FHU InovPain, CHU Nice and Côte Azur University, Hôpital Cimiez, Nice, France;

²INSERM U1107 Migraine and Trigeminal Pain, Auvergne University, Clermont-Ferrand, France;

³StudyMetrix Research, LLC. St Peters, Missouri, USA; ⁴Pfizer Inc., Paris, France; ⁵Pfizer Inc., New York, New York, USA; ⁶Pfizer Inc., Groton, Connecticut, USA; ⁷Pfizer Inc., Collegeville, Pennsylvania, USA

Correspondence:

Catherine Nalpas (catherine.nalpas@pfizer.com).

Supplemental Table 1. Institutional review boards or independent ethics committees that approved the study protocol.

Country	IRB/IEC
Australia	Bellberry HREC 123 Glen Osmond Road Eastwood, Adelaide, South Australia 5063 AUSTRALIA
Australia	Alfred Hospital Ethics Committee 55 Commercial Road Melbourne, Victoria 3004 AUSTRALIA
Austria	Ethikkommission Medizinische Universität Wien Borschkegasse 8b/6 Wien, 1090 AUSTRIA
Belgium	Ethics Committee of AZ Groeninge President Kennedylaan 4 Kortrijk, 8500 BELGIUM
Canada	Conjoint Health Research Ethics Board (CHREB) 2500 University Drive NW, Research Services - University of Calgary Calgary, AB T2N 1N4 CANADA
Canada	Advarra 372 Hollandview Trail, Suite 300 Aurora, ON L4G 0A5 CANADA
Denmark	De Videnskabsetiske Medicinske Komiteer Orestads Boulevard 5, Bygning 37K, st. Kobenhavn S, 2300 DENMARK
Finland	Valtakunnallinen lääketieteellinen tutkimuseettinen toimikunta TUKIJA Ratapihantie 9, PO Box 43 Helsinki, 00521 FINLAND
France	Comité de protection des personnes Sud-Méditerranée II Hôpital Sainte Marguerite Pavillon 9 - 1er étage, 270, bld Sainte Marguerite Marseille, 13009 FRANCE
Germany	Ethikkommission bei der Landesärztekammer Hessen Hanauer Landstraße 152 Frankfurt am Main, Hessen 60314 GERMANY
Italy	Comitato Etico Lazio Area 5 Via Elio Chianesi n. 53 Rome, Rome 00144 ITALY
Mexico	Unidad de Investigación en Salud de Chihuahua S.C. Trasviña y Retes 1317, Col. San Felipe

	Chihuahua, Chihuahua 31203 MEXICO
Mexico	Hospital Hispano S.A. de C.V. Pedro Moreno No. 934, Zona Centro Guadalajara, Jalisco CP 44100 MEXICO
Mexico	Oaxaca Site Management Organization S.C. Humboldt 302, Col. Centro Oaxaca de Juarez, Oaxaca 68000 MEXICO
Mexico	Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V Calle Volcán Popocatepetl No. 4571, Colonia el Colli Urbano Zapopan, Jalisco 45070 MEXICO
Poland	Komisja Bioetyczna Państwowego Instytutu Medycznego MSWiA ul. Wołoska 137 Warszawa, 02-507 POLAND
Spain	CEIm de Navarra Irunlarrea, 3, Pabellón de Docencia Pamplona, 31008 SPAIN
Sweden	Etikprövningsmyndigheten Box 2110 Uppsala, 750 02 SWEDEN
United Kingdom	South Central - Oxford B Research Ethics Committee Health Research Authority 2 Redman Place Stratford, E20 1JQ UNITED KINGDOM
United States	Advarra 6100 Merriweather Drive, Suite 600 Columbia, Maryland 21044 UNITED STATES
United States	Biomedical Research Alliance of New York, LLC 1981 Marcus Ave, Ste 210 Lake Success, NY 11042 UNITED STATES

IEC independent ethics committee, *IRB* institutional review board.

Supplemental Table 2. Time course of pain relief.

Time post dose	Rimegepant 75 mg <i>n</i> = 286	Placebo <i>n</i> = 284	Difference (rimegepant – placebo)
15 minutes			
n (%)	13 (4.5)	19 (6.7)	–2.1
95% CI	(2.1, 7.0)	(3.8, 9.6)	(–5.9, 1.6)
<i>p</i> value			0.2658
30 minutes			
n (%)	35 (12.2)	37 (13.0)	–0.8
95% CI	(8.4, 16.0)	(9.1, 16.9)	(–6.2, 4.7)
<i>p</i> value			0.7764
45 minutes			
n (%)	57 (19.9)	51 (18.0)	2.0
95% CI	(15.3, 24.6)	(13.5, 22.4)	(–4.5, 8.4)
<i>p</i> value			0.5478
1 hour			
n (%)	89 (31.1)	64 (22.5)	8.6
95% CI	(25.8, 36.5)	(17.7, 27.4)	(1.3, 15.8)
<i>p</i> value			0.0201
1.5 hours			
n (%)	128 (44.8)	72 (25.4)	19.4
95% CI	(39.0, 50.5)	(20.3, 30.4)	(11.7, 27.1)
<i>p</i> value			<0.0001
2 hours			
n (%)	160 (55.9)	93 (32.7)	23.2
95% CI	(50.2, 61.7)	(27.3, 38.2)	(15.3, 31.1)
<i>p</i> value			<0.0001
3 hours			
n (%)	169 (59.1)	93 (32.7)	26.3
95% CI	(53.4, 64.8)	(27.3, 38.2)	(18.5, 34.2)
<i>p</i> value			<0.0001
4 hours			
n (%)	176 (61.5)	89 (31.3)	30.2
95% CI	(55.9, 67.2)	(25.9, 36.7)	(22.4, 38.0)
<i>p</i> value			<0.0001
6 hours			
n (%)	177 (61.9)	93 (32.7)	29.1
95% CI	(56.3, 67.5)	(27.3, 38.2)	(21.3, 37.0)
<i>p</i> value			<0.0001
8 hours			
n (%)	188 (65.7)	96 (33.8)	31.9
95% CI	(60.2, 71.2)	(28.3, 39.3)	(24.2, 39.7)
<i>p</i> value			<0.0001
24 hours			
n (%)	185 (64.7)	101 (35.6)	29.1
95% CI	(59.1, 70.2)	(30.0, 41.1)	(21.3, 37.0)
<i>p</i> value			<0.0001
48 hours			
n (%)	179 (62.6)	89 (31.3)	31.2
95% CI	(57.0, 68.2)	(25.9, 36.7)	(23.5, 39.0)
<i>p</i> value			<0.0001

Participants with missing data at the time point or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 3. Time course of pain freedom.

Time post dose	Rimegepant 75 mg <i>n</i> = 286	Placebo <i>n</i> = 284	Difference (rimegepant – placebo)
15 minutes			
n (%)	1 (0.3)	1 (0.4)	0.0
95% CI	(0.0, 1.0)	(0.0, 1.0)	(–1.0, 1.0)
<i>p</i> value			0.9960
30 minutes			
n (%)	1 (0.3)	1 (0.4)	0.0
95% CI	(0.0, 1.0)	(0.0, 1.0)	(–1.0, 1.0)
<i>p</i> value			0.9960
45 minutes			
n (%)	7 (2.4)	8 (2.8)	–0.4
95% CI	(0.7, 4.2)	(0.9, 4.7)	(–3.0, 2.3)
<i>p</i> value			0.7830
1 hour			
n (%)	10 (3.5)	13 (4.6)	–1.1
95% CI	(1.4, 5.6)	(2.1, 7.0)	(–4.3, 2.2)
<i>p</i> value			0.5120
1.5 hours			
n (%)	36 (12.6)	18 (6.3)	6.2
95% CI	(8.7, 16.4)	(3.5, 9.2)	(1.5, 11.0)
<i>p</i> value			0.0103
2 hours			
n (%)	65 (22.7)	21 (7.4)	15.3
95% CI	(17.9, 27.6)	(4.4, 10.4)	(9.6, 21.1)
<i>p</i> value			<0.0001
3 hours			
n (%)	85 (29.7)	30 (10.6)	19.2
95% CI	(24.4, 35.0)	(7.0, 14.1)	(12.8, 25.5)
<i>p</i> value			<0.0001
4 hours			
n (%)	94 (32.9)	39 (13.7)	19.1
95% CI	(27.4, 38.3)	(9.7, 17.7)	(12.4, 25.9)
<i>p</i> value			<0.0001
6 hours			
n (%)	120 (42.0)	43 (15.1)	26.8
95% CI	(36.2, 47.7)	(11.0, 19.3)	(19.7, 33.9)
<i>p</i> value			<0.0001
8 hours			
n (%)	135 (47.2)	49 (17.3)	29.9
95% CI	(41.4, 53.0)	(12.9, 21.6)	(22.7, 37.2)
<i>p</i> value			<0.0001
24 hours			
n (%)	143 (50.0)	70 (24.6)	25.4
95% CI	(44.2, 55.8)	(19.6, 29.7)	(17.7, 33.0)
<i>p</i> value			<0.0001
48 hours			
n (%)	160 (55.9)	64 (22.5)	33.4
95% CI	(50.2, 61.7)	(17.7, 27.4)	(25.9, 40.9)
<i>p</i> value			<0.0001

Participants with missing data at the time point or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 4. Time course of return to normal function.^a

Time post dose	Rimegepant 75 mg <i>n</i> = 232	Placebo <i>n</i> = 237	Difference (rimegepant – placebo)
15 minutes			
n (%)	0 (0.0)	1 (0.4)	–0.4
95% CI	(NA, NA)	(0.0, 1.2)	(–1.2, 0.4)
<i>p</i> value			0.3163
30 minutes			
n (%)	3 (1.3)	5 (2.1)	–0.8
95% CI	(0.0, 2.7)	(0.3, 3.9)	(–3.2, 1.5)
<i>p</i> value			0.4934
45 minutes			
n (%)	9 (3.9)	12 (5.1)	–1.2
95% CI	(1.4, 6.4)	(2.3, 7.9)	(–4.9, 2.6)
<i>p</i> value			0.5346
1 hour			
n (%)	17 (7.3)	17 (7.2)	0.2
95% CI	(4.0, 10.7)	(3.9, 10.5)	(–4.5, 4.8)
<i>p</i> value			0.9485
1.5 hours			
n (%)	38 (16.4)	22 (9.3)	7.1
95% CI	(11.6, 21.1)	(5.6, 13.0)	(1.1, 13.1)
<i>p</i> value			0.0210
2 hours			
n (%)	67 (28.9)	30 (12.7)	16.2
95% CI	(23.0, 34.7)	(8.4, 16.9)	(9.0, 23.4)
<i>p</i> value			<0.0001
3 hours			
n (%)	79 (34.1)	32 (13.5)	20.5
95% CI	(28.0, 40.1)	(9.2, 17.9)	(13.1, 28.0)
<i>p</i> value			<0.0001
4 hours			
n (%)	92 (39.7)	46 (19.4)	20.2
95% CI	(33.4, 45.9)	(14.4, 24.4)	(12.2, 28.3)
<i>p</i> value			<0.0001
6 hours			
n (%)	108 (46.6)	43 (18.1)	28.4
95% CI	(40.1, 53.0)	(13.2, 23.0)	(20.3, 36.5)
<i>p</i> value			<0.0001
8 hours			
n (%)	114 (49.1)	49 (20.7)	28.5
95% CI	(42.7, 55.6)	(15.5, 25.8)	(20.2, 36.7)
<i>p</i> value			<0.0001
24 hours			
n (%)	131 (56.5)	63 (26.6)	29.9
95% CI	(50.1, 62.8)	(21.0, 32.2)	(21.4, 38.4)
<i>p</i> value			<0.0001
48 hours			
n (%)	136 (58.6)	58 (24.5)	34.1
95% CI	(52.3, 65.0)	(19.0, 29.9)	(25.8, 42.5)
<i>p</i> value			<0.0001

^aAmong those with any level of functional disability at time of dosing. Participants with missing data before dosing, missing data at the time point, or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 5. Time course of freedom from the most bothersome symptom.

Time post dose	Rimegepant 75 mg <i>n</i> = 286	Placebo <i>n</i> = 284	Difference (rimegepant – placebo)
15 minutes			
n (%)	10 (3.5)	14 (4.9)	–1.4
95% CI	(1.4, 5.6)	(2.4, 7.4)	(–4.7, 1.9)
<i>p</i> value			0.3943
30 minutes			
n (%)	18 (6.3)	22 (7.7)	–1.5
95% CI	(3.5, 9.1)	(4.6, 10.9)	(–5.6, 2.7)
<i>p</i> value			0.4972
45 minutes			
n (%)	30 (10.5)	28 (9.9)	0.6
95% CI	(6.9, 14.0)	(6.4, 13.3)	(–4.3, 5.6)
<i>p</i> value			0.8034
1 hour			
n (%)	43 (15.0)	31 (10.9)	4.1
95% CI	(10.9, 19.2)	(7.3, 14.5)	(–1.4, 9.6)
<i>p</i> value			0.1425
1.5 hours			
n (%)	62 (21.7)	44 (15.5)	6.2
95% CI	(16.9, 26.5)	(11.3, 19.7)	(–0.2, 12.6)
<i>p</i> value			0.0568
2 hours			
n (%)	89 (31.1)	53 (18.7)	12.5
95% CI	(25.8, 36.5)	(14.1, 23.2)	(5.4, 19.5)
<i>p</i> value			0.0005
3 hours			
n (%)	103 (36.0)	54 (19.0)	17.0
95% CI	(30.5, 41.6)	(14.5, 23.6)	(9.8, 24.2)
<i>p</i> value			<0.0001
4 hours			
n (%)	113 (39.5)	66 (23.2)	16.3
95% CI	(33.8, 45.2)	(18.3, 28.2)	(8.8, 23.8)
<i>p</i> value			<0.0001
6 hours			
n (%)	129 (45.1)	76 (26.8)	18.3
95% CI	(39.3, 50.9)	(21.6, 31.9)	(10.6, 26.1)
<i>p</i> value			<0.0001
8 hours			
n (%)	137 (47.9)	75 (26.4)	21.5
95% CI	(42.1, 53.7)	(21.3, 31.5)	(13.8, 29.2)
<i>p</i> value			<0.0001
24 hours			
n (%)	143 (50.0)	81 (28.5)	21.5
95% CI	(44.2, 55.8)	(23.3, 33.8)	(13.7, 29.3)
<i>p</i> value			<0.0001
48 hours			
n (%)	140 (49.0)	73 (25.7)	23.2
95% CI	(43.2, 54.7)	(20.6, 30.8)	(15.5, 31.0)
<i>p</i> value			<0.0001

Participants with missing data before dosing, missing data at the time point, or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 6. Time course of freedom from phonophobia^a.

Time post dose	Rimegepant 75 mg <i>n</i> = 150	Placebo <i>n</i> = 164	Difference (rimegepant – placebo)
15 minutes			
n (%)	5 (3.3)	5 (3.0)	0.3
95% CI	(0.5, 6.2)	(0.4, 5.7)	(–3.6, 4.2)
<i>p</i> value			0.8862
30 minutes			
n (%)	6 (4.0)	11 (6.7)	–2.7
95% CI	(0.9, 7.1)	(2.9, 10.5)	(–7.7, 2.2)
<i>p</i> value			0.2836
45 minutes			
n (%)	18 (12.0)	13 (7.9)	4.1
95% CI	(6.8, 17.2)	(3.8, 12.1)	(–2.6, 10.7)
<i>p</i> value			0.2295
1 hour			
n (%)	23 (15.3)	22 (13.4)	1.9
95% CI	(9.6, 21.1)	(8.2, 18.6)	(–5.9, 9.7)
<i>p</i> value			0.6286
1.5 hours			
n (%)	35 (23.3)	32 (19.5)	3.8
95% CI	(16.6, 30.1)	(13.4, 25.6)	(–5.3, 12.9)
<i>p</i> value			0.4099
2 hours			
n (%)	52 (34.7)	39 (23.8)	10.9
95% CI	(27.1, 42.3)	(17.3, 30.3)	(0.9, 20.9)
<i>p</i> value			0.0333
3 hours			
n (%)	66 (44.0)	44 (26.8)	17.2
95% CI	(36.1, 51.9)	(20.0, 33.6)	(6.7, 27.6)
<i>p</i> value			0.0013
4 hours			
n (%)	74 (49.3)	43 (26.2)	23.1
95% CI	(41.3, 57.3)	(19.5, 33.0)	(12.7, 33.6)
<i>p</i> value			<0.0001
6 hours			
n (%)	78 (52.0)	50 (30.5)	21.5
95% CI	(44.0, 60.0)	(23.4, 37.5)	(10.9, 32.2)
<i>p</i> value			<0.0001
8 hours			
n (%)	79 (52.7)	52 (31.7)	21.0
95% CI	(44.7, 60.7)	(24.6, 38.8)	(10.3, 31.7)
<i>p</i> value			<0.0001
24 hours			
n (%)	90 (60.0)	58 (35.4)	24.6
95% CI	(52.2, 67.8)	(28.0, 42.7)	(13.9, 35.4)
<i>p</i> value			<0.0001
48 hours			
n (%)	87 (58.0)	57 (34.8)	23.2
95% CI	(50.1, 65.9)	(27.5, 42.0)	(12.5, 34.0)
<i>p</i> value			<0.0001

^aAmong those with phonophobia at the time of dosing. Participants with missing data at the time point, or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 7. Time course of freedom from photophobia^a.

Time post dose	Rimegepant 75 mg <i>n</i> = 184	Placebo <i>n</i> = 197	Difference (rimegepant – placebo)
15 minutes			
n (%)	2 (1.1)	5 (2.5)	–1.5
95% CI	(0.0, 2.6)	(0.3, 4.7)	(–4.1, 1.2)
<i>p</i> value			0.2847
30 minutes			
n (%)	7 (3.8)	12 (6.1)	–2.3
95% CI	(1.0, 6.6)	(2.8, 9.4)	(–6.6, 2.0)
<i>p</i> value			0.3012
45 minutes			
n (%)	17 (9.2)	18 (9.1)	0.1
95% CI	(5.1, 13.4)	(5.1, 13.2)	(–5.7, 5.9)
<i>p</i> value			0.9725
1 hour			
n (%)	27 (14.7)	22 (11.2)	3.5
95% CI	(9.6, 19.8)	(6.8, 15.6)	(–3.2, 10.3)
<i>p</i> value			0.3082
1.5 hours			
n (%)	42 (22.8)	26 (13.2)	9.6
95% CI	(16.8, 28.9)	(8.5, 17.9)	(1.9, 17.3)
<i>p</i> value			0.0141
2 hours			
n (%)	66 (35.9)	33 (16.8)	19.1
95% CI	(28.9, 42.8)	(11.5, 22.0)	(10.4, 27.8)
<i>p</i> value			<0.0001
3 hours			
n (%)	77 (41.8)	36 (18.3)	23.6
95% CI	(34.7, 49.0)	(12.9, 23.7)	(14.6, 32.5)
<i>p</i> value			<0.0001
4 hours			
n (%)	88 (47.8)	44 (22.3)	25.5
95% CI	(40.6, 55.0)	(16.5, 28.2)	(16.2, 34.8)
<i>p</i> value			<0.0001
6 hours			
n (%)	90 (48.9)	60 (30.5)	18.5
95% CI	(41.7, 56.1)	(24.0, 36.9)	(8.8, 28.1)
<i>p</i> value			0.0002
8 hours			
n (%)	99 (53.8)	55 (27.9)	25.9
95% CI	(46.6, 61.0)	(21.7, 34.2)	(16.3, 35.4)
<i>p</i> value			<0.0001
24 hours			
n (%)	109 (59.2)	60 (30.5)	28.8
95% CI	(52.1, 66.3)	(24.0, 36.9)	(19.2, 38.4)
<i>p</i> value			<0.0001
48 hours			
n (%)	104 (56.5)	62 (31.5)	25.0
95% CI	(49.4, 63.7)	(25.0, 38.0)	(15.4, 34.7)
<i>p</i> value			<0.0001

^aAmong those with photophobia at the time of dosing. Participants with missing data at the time point, or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 8. Time course of freedom from nausea^a.

Time post dose	Rimegepant 75 mg <i>n</i> = 144	Placebo <i>n</i> = 147	Difference (rimegepant – placebo)
15 minutes			
n (%)	7 (4.9)	14 (9.5)	–4.7
95% CI	(1.3, 8.4)	(4.8, 14.3)	(–10.6, 1.2)
<i>p</i> value			0.1216
30 minutes			
n (%)	19 (13.2)	25 (17.0)	–3.8
95% CI	(7.7, 18.7)	(10.9, 23.1)	(–12.0, 4.4)
<i>p</i> value			0.3629
45 minutes			
n (%)	30 (20.8)	26 (17.7)	3.1
95% CI	(14.2, 27.5)	(11.5, 23.9)	(–5.9, 12.2)
<i>p</i> value			0.4960
1 hour			
n (%)	38 (26.4)	31 (21.1)	5.3
95% CI	(19.2, 33.6)	(14.5, 27.7)	(–4.5, 15.1)
<i>p</i> value			0.2873
1.5 hours			
n (%)	55 (38.2)	44 (29.9)	8.3
95% CI	(30.3, 46.1)	(22.5, 37.3)	(–2.6, 19.1)
<i>p</i> value			0.1357
2 hours			
n (%)	69 (47.9)	52 (35.4)	12.5
95% CI	(39.8, 56.1)	(27.6, 43.1)	(1.3, 23.8)
<i>p</i> value			0.0287
3 hours			
n (%)	76 (52.8)	41 (27.9)	24.9
95% CI	(44.6, 60.9)	(20.6, 35.1)	(14.0, 35.8)
<i>p</i> value			<0.0001
4 hours			
n (%)	81 (56.3)	47 (32.0)	24.3
95% CI	(48.1, 64.4)	(24.4, 39.5)	(13.2, 35.3)
<i>p</i> value			<0.0001
6 hours			
n (%)	92 (63.9)	51 (34.7)	29.2
95% CI	(56.0, 71.7)	(27.0, 42.4)	(18.2, 40.2)
<i>p</i> value			<0.0001
8 hours			
n (%)	94 (65.3)	48 (32.7)	32.6
95% CI	(57.5, 73.1)	(25.1, 40.2)	(21.8, 43.5)
<i>p</i> value			<0.0001
24 hours			
n (%)	93 (64.6)	52 (35.4)	29.2
95% CI	(56.8, 72.4)	(27.6, 43.1)	(18.2, 40.2)
<i>p</i> value			<0.0001
48 hours			
n (%)	92 (63.9)	48 (32.7)	31.2
95% CI	(56.0, 71.7)	(25.1, 40.2)	(20.3, 42.1)
<i>p</i> value			<0.0001

^aAmong those with nausea at the time of dosing. Participants with missing data at the time point, or took rescue medication at or before the time point were imputed as failures. *CI* confidence interval.

Supplemental Table 9. List of principal investigators by country.

Country	Principal Investigators ^a
Australia	Matthew Green, Jason Ray, Robert Scott
Austria	Gregor Brössner, Sonja-Maria Tesar, Christian Wöber
Belgium	Tim Kelderman, Nina De Klippel, Koen Paemeleire, Simona Liliana Sava, Jan Versijpt
Canada	Naresh Aggarwal, Farnaz Amoozegar, Manon Bouchard, James SJ Kim, Jérôme Nadeau, Raphael Poulin-Robitaille
Denmark	Messoud Ashina, Signe Bruun Munksgaard, Dorte Phillip, Lis Pluss, Tobias Sejbaek
Finland	Mikko Kallela, Petra Keski-Säntti, Markku Nissila, Marja-Liisa Sumelahti
France	Christelle Creac'h, Genevieve Demarquay, Anne Donnet, Pierric Giraud, Michel Lanteri-Minet, Christian Lucas, Xavier Moisset, Caroline Roos
Germany	Andreas Böger, Charly Gaul, Robert Fleischmann, Hartmut Goebel, Bianca Raffaelli, Tanja Schlereth, Till Sprenger, Maureen Steinicke, Peter Storch
Italy	Piero Barbanti, Massimo Filippi, Licia Grazi, Simona Guerzoni, Maria Pia Prudenzeno, Antonio Russo, Cristina Tassorelli, Fabrizio Vernieri
Mexico	Adolfo Leyva Rendon, Sandra Quinones Aguilar, Sarug Reyes, Daniel San Juan-Orta
Poland	Magdalena Boczarska-Jedynak, Kamila Bojakowska, Izabela Domitrz, Krystyna Gospodarczyk-Szot, Anna Gryglas-Dworak, Agata Klosek, Lukasz Kmiecik, Pawel Lisewski, Agnieszka Meller, Ilona Palka-Kisielowska, Agnieszka Pojmanska
Spain	Rafael Arroyo, Javier Díaz de Terán, Carmen Gonzalez Oria, Jose Miguel Lainez, Julio Pascual Gómez, Patricia Pozo-Rosich
Sweden	David Ellingsen, Marcus Hjort, Helena Litorp, Ake Olsson, Gürdal Sahin
United Kingdom	Anish Bahra, Fazel Butt, Conor Clerkin-Oliver, Peter Goadsby, Amardeep Heer, Terence McLoughlin, Martin Palin
United States	Patrick Dennis, Michael DiGiovanna, Andrew Feldman, Marshall Freeman, Seth Hepner, Muhammad Irfan, Ramsey Joudeh, Artem Kaplan, Arifulla Khan, James Kopp, David Kudrow, Agustin J Latorre, Peter McAllister, Antonio Mendes, Bernard Miller, Gretchen Mitchell, Brittany Newton, Jelena Pavlovic, Anthony Puopolo, Nazia Rahman, Harvey Resnick, Rebecca Rivard, Joel Saper, Timothy Smith, Guy Strauss, Kelly Taylor, Ben Thomas, Haydn Thomas, David True, Esther Young

^aAlphabetical by last name.